Brought to you by 
3D will generate compound libraries for DuPont Pharma
17 Aug 2000
Executive Summary
3-Dimensional Pharmaceuticals (combinatorial drug discovery) will use its iterative DirectedDiversity technology to produce compound libraries suited to DuPont Pharmaceuticals' biological targets. The agreement runs through 2001, and the term can be extended at DuPont's option.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
3D will generate compound libraries for DuPont Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice